Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Misses Revenue Estimates
CoDiagnostics (CODX) delivered earnings and revenue surprises of +8.00% and -45.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?